Liver cancer showdown: which combo causes less harm?
NCT ID NCT07277192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 562 people with advanced liver cancer to compare two treatment combinations: one using HAIC (chemotherapy directly into the liver) plus immunotherapy and targeted drugs, and the other using TACE (a procedure that blocks blood flow to the tumor) plus the same drugs. The main goal was to see which approach caused less liver injury and helped patients live longer. Results help doctors choose the safer, more effective option for managing this serious disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIC(HEPATIC ARTERY INFUSION CHEMOTHERAPY) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Spirulina's secret protein may shield the liver during surgery
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver